OmniPod Insulin Pump Lawsuit

Omnipod insulin pump claims focus on whether manufacturing defects caused certain Pods to deliver less insulin than users needed to safely control their blood sugar.

Unlike a diabetes regimen that may use long-acting insulin together with an insulin pen, pump therapy relies on the device to provide ongoing insulin delivery, meaning a disruption can cause high blood glucose levels to develop quickly.

Insulet has identified manufacturing problems involving damaged cannulas that may allow insulin to leak instead of entering the body, and the leakage may go unnoticed while a person continues to believe they are receiving enough insulin.

Regulatory reporting has included hundreds of reports potentially associated with Omnipod product problems, while the 2026 recalls have separately been associated with confirmed serious adverse events involving hyperglycemia, hospitalization, and patients who experienced diabetic ketoacidosis (DKA).

DKA is a serious complication of insulin deficiency that requires prompt medical treatment and can become life-threatening in severe cases.

The manufacturing problems have also become relevant to both personal injury and wrongful death claims and separate securities litigation involving allegations about Insulet’s representations concerning the safety and quality of its Omnipod products.

Potential Omnipod claims may involve allegations that:

• Defective manufacturing processes damaged the cannula responsible for delivering insulin into the body.
• Insulin leakage caused users to receive less insulin than expected, increasing the risk of severe hyperglycemia and DKA.
• The defect could occur without a clear warning or alarm, making it difficult for users to identify the source of rising blood sugar.
• Insulet failed to adequately identify, prevent, or communicate product quality problems before affected Pods reached patients.

Personal injury claims may be available when evidence connects an Omnipod malfunction with DKA, hospitalization, or another serious injury, while families may investigate wrongful death claims when an alleged device failure contributed to a fatal outcome.

Separate securities lawsuits allege that Insulet made false or misleading statements concerning the safety and quality of its Omnipod products, although those investor claims are distinct from lawsuits filed by injured patients.

As Omnipod litigation develops, medical records, glucose data, Pod lot information, and evidence of insulin under-delivery may help determine whether a defective device contributed to an individual’s injuries.

Current Omnipod Lawsuit Status

Omnipod product liability litigation remains in the early stages, and there is currently no multidistrict litigation (MDL) consolidating claims against Insulet Corporation.

One existing case, Sciandra v. Insulet Corporation, involves product liability and negligence claims arising from the death of an Omnipod 5 user who allegedly developed severe diabetic ketoacidosis after the device failed to deliver insulin as intended.

That lawsuit was filed before the 2026 Omnipod recalls and should not be treated as a claim arising from the recently identified cannula defects.

Separately, investors filed a securities class action against Insulet in July 2026 alleging that the company made false or misleading statements about the quality and safety of its Omnipod products, but that proceeding does not involve compensation claims for injured patients.

Additional personal injury and wrongful death lawsuits may be filed as attorneys investigate whether recalled Omnipod Pods contributed to diabetic ketoacidosis, hospitalization, or other serious injuries.

Insulet Corporation was formed in 2000 with the goal of developing a wearable alternative to conventional insulin pump therapy for people who require ongoing insulin treatment.

The FDA cleared the original Omnipod Insulin Management System in January 2005, and Insulet began commercial sales in the United States later that year.

From a medical standpoint, Omnipod entered the market as a form of continuous subcutaneous insulin infusion intended to help patients maintain appropriate glucose control when insulin is delivered properly.

Over the following two decades, the product developed alongside advances in diabetes care, including wider adoption of continuous glucose monitoring and automated approaches to insulin management.

Omnipod has since become an established prescription diabetes device platform in which patients receive disposable Pods, commonly supplied in a pod box, and transition to a new pod as part of their prescribed treatment schedule.

The history and medical use of Omnipod include:

• Insulet was founded in 2000 and focused much of its early development on creating a disposable, wearable insulin delivery product.
• The original Omnipod received FDA clearance in 2005 before becoming commercially available in the United States that same year.
• The product was developed for people with insulin-dependent diabetes as an alternative to traditional pump systems that relied on external tubing.
• Omnipod technology has continued to develop alongside changes in glucose monitoring, digital diabetes management, and automated insulin therapy.
• The Omnipod platform has remained centered on disposable Pod therapy while its related diabetes-management technology has evolved over time.

How the Omnipod System Delivers Insulin

The Omnipod system delivers rapid-acting insulin through a small cannula placed beneath the skin, allowing continuous subcutaneous delivery throughout the period the Pod is worn.

Rather than relying on long-acting insulin for background coverage, the system provides basal insulin in small amounts across the day and night according to the user’s programmed therapy settings.

Depending on the Omnipod system and prescribed treatment plan, basal insulin can be delivered at set and variable rates to account for changing insulin needs.

Users can also administer additional insulin doses for meals or elevated glucose levels based on their prescribed settings and appropriate glucose monitoring.

When a new Pod is prepared, the user removes it from the pod tray lid, fills it with insulin, applies it to the body, and activates the automated cannula insertion process.

Once activated, the Pod communicates with its compatible controller or mobile application to manage programmed insulin delivery during wear.

Because the system depends on consistent delivery through the cannula, proper placement, Pod function, and ongoing glucose monitoring are important parts of maintaining effective insulin therapy.

Insulet issued two major medical device correction actions in 2026 after identifying manufacturing defects that could interfere with insulin delivery from certain Omnipod Pods.

Across the two actions, more than 8 million Pods were affected, including certain Omnipod 5, OmniPod DASH, and Omnipod Eros products.

The defects involved damage to the soft cannula that carries insulin from the Pod into the body, allowing insulin to leak rather than being delivered as intended.

Insulin leakage can be difficult to detect and may occur without an alarm, although some Omnipod 5 users in Automated Mode may receive an automated delivery restriction alert when glucose levels do not respond as expected.

The FDA has also stated that these defects do not affect continuous glucose monitoring systems or CGM readings.

The 2026 Omnipod recalls include:

• March 2026 Omnipod 5 recall: Insulet recalled certain Omnipod 5 Pods from 49 lots after discovering that some could develop a small tear in the internal tubing, or soft cannula, during manufacturing. The defect could allow insulin to leak inside the Pod and, in some cases, cause an electrical short that shuts down insulin delivery entirely. The FDA later classified the action as a Class I recall, and Insulet reported 29 serious injuries associated with the issue as of April 17, 2026.
• May 2026 Omnipod 5, DASH, and Eros recall: A separate manufacturing problem could damage the external portion of the cannula just above the skin, allowing insulin to leak outside the Pod. This action covered approximately 7 million Pods and involved Omnipod 5, Omnipod DASH, and Eros systems. Insulet reported 24 serious injuries as of May 20, 2026, and the FDA instructed users to discontinue use of any impacted Pod immediately and return unused affected Pods through Insulet’s replacement process.

How to Determine Whether an Omnipod Pod Was Recalled

Users can identify potentially recalled Omnipod devices by checking the lot number and unique device identifier printed on the Pod packaging, tray lid, or other product labeling.

Insulet and the FDA published the affected lot information for the 2026 recalls, allowing users to compare the identifying information on their Pods with the recalled product lists.

Patients should not rely only on the appearance of the Pod, because a cannula defect may not be visible before use and some affected devices may operate without an immediate alarm.

The FDA also advises patients not to use expired Pods, even when the lot is not included in the recall, because expired devices may not function as intended.

If a Pod is identified as affected while it is being worn, users should immediately change to a replacement Pod and follow Insulet’s recall instructions.

People who no longer have enough unaffected Pods should contact Insulet about replacements and follow their healthcare provider’s guidance regarding alternative insulin delivery and glucose monitoring until replacement Pods are available.

Omnipod Pods depend on an intact cannula to move insulin from the device into the tissue beneath the skin.

If the cannula is torn, bent, or otherwise damaged, some or all of the programmed insulin dose may leak instead of reaching the body.

Because the Pod can continue appearing to function normally, a user may believe insulin is being delivered even as blood glucose levels continue to rise.

Insulin under-delivery can become especially dangerous for people who rely on the Pod for their basal insulin needs throughout the day and night.

Without enough circulating insulin, the body may begin breaking down fat for energy and producing ketones, increasing the risk of diabetic ketoacidosis.

A defective Omnipod Pod may interfere with insulin delivery through:

• Internal cannula damage: A tear inside the Pod can allow insulin to leak before it reaches the infusion site.
• External cannula damage: A tear near the skin can cause insulin to leak onto the skin or adhesive instead of entering the body.
• Partial insulin delivery: Some insulin may still reach the user, making the malfunction harder to recognize while delivering less insulin than prescribed.
• Complete interruption of delivery: Certain failures may stop insulin delivery entirely, including situations where leaked insulin contributes to an electrical problem inside the Pod.
• Delayed recognition: The Pod may not immediately produce an alarm, leaving rising glucose levels as one of the first signs that insulin delivery has been disrupted.

As insulin deficiency continues, glucose can accumulate in the bloodstream while the body’s cells remain unable to use it effectively for energy.

Rising glucose and ketone levels can progress to severe hyperglycemia, dehydration, metabolic imbalance, and diabetic ketoacidosis if the delivery problem is not identified and corrected.

Medical records, CGM data, Pod history, and evidence of insulin leakage may help determine whether an Omnipod malfunction contributed to a serious medical event.

When an Omnipod is not working properly, insulin delivery may be reduced or interrupted without the user immediately recognizing the problem.

Without enough insulin, blood glucose levels can rise rapidly and place the body under increasing metabolic stress.

Early symptoms may include excessive thirst, frequent urination, fatigue, nausea, and other signs of worsening hyperglycemia.

If the problem continues, serious complications may develop and require emergency medical treatment or hospitalization.

Potential Omnipod injuries and complications may include:

• Severe hyperglycemia
• Diabetic ketoacidosis (DKA)
• Hyperglycemic hyperosmolar syndrome
• Dehydration
• Nausea and vomiting
• Altered mental status
• Loss of consciousness
• Electrolyte imbalances
• Acute kidney injury
• Emergency room treatment
• Hospitalization or intensive care
• Death in severe cases

Diabetic Ketoacidosis After Omnipod Failure

Diabetic ketoacidosis can develop when an Omnipod failure prevents the body from receiving enough insulin to regulate blood glucose and use glucose for energy.

Without sufficient insulin, the body begins breaking down fat, producing acidic substances called ketones that can build up in the bloodstream.

Because pump users typically rely on rapid-acting insulin rather than a separate source of long-acting insulin, an interruption in delivery can cause glucose and ketone levels to worsen quickly.

Symptoms may include intense thirst, frequent urination, nausea, vomiting, abdominal pain, rapid breathing, confusion, and extreme fatigue.

DKA is a medical emergency that generally requires intravenous fluids, insulin, electrolyte management, and close monitoring in a hospital setting.

Severe cases can lead to dehydration, acute kidney injury, cerebral complications, loss of consciousness, or death if treatment is delayed.

When DKA follows a suspected Omnipod malfunction, medical records, glucose and ketone data, device information, and the timing of insulin-delivery problems may help determine whether the Pod contributed to the event.

Individuals who suffered a serious injury after using an Omnipod insulin pump may qualify to pursue a product liability claim if evidence suggests the device failed to deliver insulin as intended.

Potential claims may involve users of recalled Omnipod 5, DASH, or Eros Pods that experienced cannula damage, insulin leakage, or another delivery failure.

A stronger claim may exist when the device problem was followed by severe hyperglycemia, diabetic ketoacidosis, hospitalization, intensive care, or another documented complication.

Medical records showing rising glucose levels, ketone production, emergency treatment, and insulin-related complications can help establish the timing and severity of the event.

Pod lot information, packaging, controller or app data, CGM records, and communications with Insulet may also help connect the injury to a specific device.

Families may be able to investigate wrongful death claims when an alleged Omnipod failure contributed to a fatal medical event.

Eligibility depends on the facts of each case, including the device used, the nature of the malfunction, the resulting injury, and the applicable state filing deadline.

Evidence in an Omnipod Insulin Pump Claim

Evidence can help establish which Omnipod product was used, whether it was affected by a recall or malfunction, and how the device failure may have contributed to the resulting injury.

Medical and device records are especially important when a claim involves insulin under-delivery, rising glucose levels, diabetic ketoacidosis, or hospitalization.

Preserving available product information and treatment records can also help attorneys and medical experts evaluate the timing between the suspected malfunction and the medical event.

Relevant evidence may include:

• Medical records documenting the injury and treatment
• Records identifying the Omnipod product used
• Glucose monitoring and diabetes management records
• Device data or information related to the suspected malfunction
• Communications with Insulet or healthcare providers
• Recall, replacement, or product notification records
• Photographs or other documentation of a suspected device problem
• Records of medical expenses, lost income, and other damages

Potential Compensation in an Omnipod Lawsuit

Damages are the financial and non-financial losses a person may seek to recover through a product liability claim.

In an Omnipod lawsuit, compensation may account for both the immediate effects of the injury and losses that continue after the initial medical event.

Attorneys typically assess damages by reviewing medical records, treatment costs, employment records, prognosis, and evidence showing how the injury affected the person’s daily life.

Future losses may require input from medical, vocational, or economic experts depending on the severity of the injury and expected long-term needs.

The amount of compensation available varies by case and depends on factors such as the extent of the injury, available evidence, applicable state law, and whether the Omnipod failure can be connected to the resulting harm.

Potential damages may include:

• Past and future medical expenses
• Lost wages and other income
• Reduced earning capacity
• Pain and suffering
• Emotional distress
• Permanent impairment or disability
• Loss of enjoyment of life
• Out-of-pocket expenses related to the injury
• Wrongful death damages for qualifying surviving family members

TorHoerman Law is investigating potential claims involving people who suffered serious injuries after using defective or recalled Omnipod insulin pump products.

Individuals who experienced diabetic ketoacidosis, severe hyperglycemia, hospitalization, or other complications may be able to pursue compensation if evidence shows an Omnipod failure contributed to their injuries.

An Omnipod recall lawyer can review medical records, device information, glucose data, and other evidence to determine whether a potential product liability claim may be available.

TorHoerman Law can also evaluate the damages associated with the injury and identify the parties that may be legally responsible.

There are no upfront costs required to hire TorHoerman Law for an Omnipod claim.

Cases are handled on a contingency fee basis, meaning attorney fees are collected only if compensation is recovered.

Contact TorHoerman Law for a free consultation to discuss an Omnipod insulin pump injury and learn more about your legal options.